TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03494621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protecting Babies While they Sleep Curriculum
Description: The intervention curriculum derives from information gathered at previously conducted focus groups and interviews, which aimed to ascertain the role of caregiver knowledge, beliefs, and access to resources in implementation of infant safe sleep practices. .
Study: NCT04387903

Intervention type: PROCEDURE
Intervention: Surgical re-interventionafter pancreaticoduodenectomy
Description: Mandatory surgical management of complications after pancreatico-duodenectomy through peritoneal lavage, draiange, repair of fistula, completion pancreatectomy, control of bleeding, bowel resection, and feeding jejunostomy.

Intervention type: PROCEDURE
Intervention: Surgical re-interventionafter pancreaticoduodenectomy
Description: Mandatory surgical management of complications after pancreatico-duodenectomy through peritoneal lavage, draiange, repair of fistula, completion pancreatectomy, control of bleeding, bowel resection, and feeding jejunostomy.
Study: NCT01586533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoenasa-1:4
Description: Zoenasa Rectal Gel (4.0g mesalamine \[5-ASA\], 1.0g N-acetylcysteine \[NAC\]; 60ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine Enema
Description: Mesalamine Rectal Suspension Enema (4.0g mesalamine \[5-ASA\], 60ml)
Study: NCT02712307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenoxymethylpenicillin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin
Study: NCT03586141

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pronto® hemoglobin measurement tool
Description: All patients who are planned to undergo elective surgery come to the preoperative anesthetic ambulance. They are all measured by the Pronto® hemoglobin measurement tool
Study: NCT02189369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 3 embryo transfer
Description: Extraction of endometrial fluid, analysis of prostaglandine and Day 3 embryo transfer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 3 embryo transfer
Description: Extraction of endometrial fluid, analysis of prostaglandine and Day 3 embryo transfer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 3 embryo transfer
Description: Extraction of endometrial fluid, analysis of prostaglandine and Day 3 embryo transfer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 3 embryo transfer
Description: Extraction of endometrial fluid, analysis of prostaglandine and Day 3 embryo transfer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 5 embryo transfer
Description: Extraction of endometrial fluid, analysis of prostaglandine and Day 5 embryo transfer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 5 embryo transfer
Description: Extraction of endometrial fluid, analysis of prostaglandine and Day 5 embryo transfer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 5 embryo transfer
Description: Extraction of endometrial fluid, analysis of prostaglandine and Day 5 embryo transfer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 5 embryo transfer
Description: Extraction of endometrial fluid, analysis of prostaglandine and Day 5 embryo transfer
Study: NCT03628183

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrolysate Infant Formula 1
Description: Feed ad lib

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolysate Infant Formula 2
Description: Feed ad lib
Study: NCT00985283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive home visit
Description: in-home visit by a trained occupational therapist to assess older adult's living context and occupational performance and to provide recommendations for changes or continuation of behavior or context

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: minimal intervention
Description: provision of information related to services and health promotion for older adults as a low-cost minimal alternative to the intervention
Study: NCT00487552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook Magnetic Anastomosis Device (MAD) with Stent
Description: Gastro-jejunal anastomosis
Study: NCT01990313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC+S
Description: The Model 37604 Activa PC+S is a multiprogrammable device that can deliver therapeutic electrical stimulation and record bioelectric signals from leads implanted in the brain.
Study: NCT02264236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P10s-PADRE vaccine
Description: P10s-PADRE vaccine combined with MONTANIDE™ ISA 51 VG Chemotherapy Subcutaneous injection at weeks 2, 3, 5, and 6. 3-Week Interval Immunotherapy Subcutaneous injection at weeks 2, 3, and 4. 2-Week Interval Immunotherapy Subcutaneous injection at weeks 3, 4, and 5.
Study: NCT02406274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Spectral Mammography (CESM)
Description: Women presenting to MSKCC with a palpable abnormality within the breast either self palpated \& or palpated by their physician will be offered CESM instead of FFDM alone. The breast imager assigned to care for the patient will interpret the low energy images (including any additional views they routinely obtain) \& record their findings. They will then interpret the CESM \& record those results. As per standard of care, the patient will have a targeted ultrasound as well. Appropriate clinical recommendations will be made. In patients with no specific imaging findings, follow-up will be determined by the degree of suspicion of the palpable finding \& will either be called negative \& followed clinically if not suspicious, or will go on to MRI , percutaneous biopsy by a surgeon or surgical biopsy if suspicious.
Study: NCT03418181

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Haemodialysis
Description: Thrice weekly dialysis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incremental dialysis
Description: Individualised dialysis dose according to native kidney function.
Study: NCT02893488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/ABC/3TC FDC DISPERSIBLE TABLET
Description: DTG/ABC/3TC FDC dispersible tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/ABC/3TC FDC DISPERSIBLE TABLET
Description: DTG/ABC/3TC FDC dispersible tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/ABC/3TC FDC DISPERSIBLE TABLET
Description: DTG/ABC/3TC FDC dispersible tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/ABC/3TC FDC DISPERSIBLE TABLET
Description: DTG/ABC/3TC FDC dispersible tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/ABC/3TC FDC DISPERSIBLE TABLET
Description: DTG/ABC/3TC FDC dispersible tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPZICOM (ABC/3TC)
Description: EPZICOM will be available as orange, film coated, modified capsule shaped tablets, debossed with GS FC2 on one side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPZICOM (ABC/3TC)
Description: EPZICOM will be available as orange, film coated, modified capsule shaped tablets, debossed with GS FC2 on one side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPZICOM (ABC/3TC)
Description: EPZICOM will be available as orange, film coated, modified capsule shaped tablets, debossed with GS FC2 on one side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPZICOM (ABC/3TC)
Description: EPZICOM will be available as orange, film coated, modified capsule shaped tablets, debossed with GS FC2 on one side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPZICOM (ABC/3TC)
Description: EPZICOM will be available as orange, film coated, modified capsule shaped tablets, debossed with GS FC2 on one side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVICAY (DTG)
Description: TIVICAY will be available as white, round, biconvex tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVICAY (DTG)
Description: TIVICAY will be available as white, round, biconvex tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVICAY (DTG)
Description: TIVICAY will be available as white, round, biconvex tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVICAY (DTG)
Description: TIVICAY will be available as white, round, biconvex tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVICAY (DTG)
Description: TIVICAY will be available as white, round, biconvex tablets
Study: NCT04505345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training using the Systemic Lisbon Battery
Description: The Systemic Lisbon Battery comprises exercises for cognitive rehabilitation developed to describe diverse activities of daily living.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment-as-usual
Description: Treatment as usual for alcohol use disorder from Casa de Saúde do Telhal is delivered according to the Minnesota Model.
Study: NCT00332488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin
Description: Inhalation, 15U/30U, prandial
Study: NCT00780624

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: Ventilator is Bird VIP.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: Ventilator(Bird VIP) is used for NIPPV device. Non-invasive NIPPV is used in the NIPPV group instead of nCPAP in the control group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: Ventilator(Bird VIP) is used for NIPPV device. Non-invasive NIPPV is used in the NIPPV group instead of nCPAP in the control group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: Ventilator (Bird VIP, USA) is used for provide of NIPPV in the NIPPV group instead of nCPAP in the control group. The duration of NIPPV is according to the baby's respiratory condition.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: Ventilator (Bird VIP, USA) is used for provide of NIPPV in the NIPPV group instead of nCPAP in the control group. The duration of NIPPV is according to the baby's respiratory condition.
Study: NCT02055274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neupro

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neupro
Study: NCT03062995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula with added synbiotics
Description: Intervention group: Infant Formula / Follow-On formula with partially hydrolysed cow's milk protein supplemented with prebiotics and probiotics.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Infant formula
Description: Control group: Standard Infant Formula / Follow-On formula with intact cow's milk protein (only standard ingredients, without addition of pre- and probiotics).
Study: NCT04494594

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Drinks:Ration app
Description: Drinks:Ration (www.drinksration.app; formerly called InDEx) app has been developed following the Medical Research Council Complex Intervention Guidelines and using co-design methodology by the King's Centre for Military Health Research (at King's College London) and the University of Liverpool, supported by experts in smartphone app development, epidemiology, addiction psychiatry, and military mental health. The app is designed to support veterans drinking at a hazardous or harmful level by providing detailed advice and support over a minimum of 28-day period. The app is theoretically underpinned to enhance participants motivation and self-efficacy in modifying their alcohol consumption by means of Behaviour Change Theory in the content displayed, and the messaging sent to participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Drinks:Ration app
Description: Drinks:Ration (www.drinksration.app; formerly called InDEx) app has been developed following the Medical Research Council Complex Intervention Guidelines and using co-design methodology by the King's Centre for Military Health Research (at King's College London) and the University of Liverpool, supported by experts in smartphone app development, epidemiology, addiction psychiatry, and military mental health. The app is designed to support veterans drinking at a hazardous or harmful level by providing detailed advice and support over a minimum of 28-day period. The app is theoretically underpinned to enhance participants motivation and self-efficacy in modifying their alcohol consumption by means of Behaviour Change Theory in the content displayed, and the messaging sent to participants.
Study: NCT02800941

Intervention type: DRUG
Intervention: Oral anticoagulant treatment
Description: The treatment is delivered according to the usual practice.
Study: NCT03489941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EM-100
Description: Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zaditor®
Description: Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
Study: NCT04548388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: A specialist physiotherapist in neurological rehabilitation provided the Bobath approach individually to each patients in both groups. Bobath approach included 3 days a week over a total of 12 sessions for four weeks. The Bobath approach consisted of about individual one hour session.~In addition to the Bobath approach, the subjects in the study group received WBV for 20 minutes a day, 2 days a week. The frequency of the device was increased by 5 Hz every week, starting the treatment with 30 Hz. Whole body vibration application was performed on a platform (Power Plate Pro5®) that provides vertical vibration. Two different practice positions were chosen as standing and semi-squatting. In order to prevent muscle fatigue, the set consisting of 1 minute of application - 1 minute of rest in each position was applied for a total of 10 minutes with 5 repetitions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: A specialist physiotherapist in neurological rehabilitation provided the Bobath approach individually to each patients in both groups. Bobath approach included 3 days a week over a total of 12 sessions for four weeks. The Bobath approach consisted of about individual one hour session.~In addition to the Bobath approach, the subjects in the study group received WBV for 20 minutes a day, 2 days a week. The frequency of the device was increased by 5 Hz every week, starting the treatment with 30 Hz. Whole body vibration application was performed on a platform (Power Plate Pro5®) that provides vertical vibration. Two different practice positions were chosen as standing and semi-squatting. In order to prevent muscle fatigue, the set consisting of 1 minute of application - 1 minute of rest in each position was applied for a total of 10 minutes with 5 repetitions
Study: NCT04026932

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Listening to unmodified music
Description: Listening to unmodified music for at least 2 hours a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to modified tinnitus relieving sound
Description: Listening to modified tinnitus relieving sound for at least 2 hours a day
Study: NCT03327961

Intervention type: DEVICE
Intervention: scaffold
Description: implantation of scaffold (eg Magmaris, Desolve, Others)
Study: NCT02893423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Using 2 Different Concentrations of Ropivacaine in Tap Block for Postoperative Analgesia for C-Section Patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Using 2 Different Concentrations of Ropivacaine in Tap Block for Postoperative Analgesia for C-Section Patients
Study: NCT02614131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2599666
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2599666
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solanezumab
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Administered IV
Study: NCT00636636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Extended Release tablets
Description: Once-Daily; 300 mg and 600 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily; 300 mg and 600 mg tablets
Study: NCT01499641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Epidural methylprednisolone 40 mg or none

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Epidural methylprednisolone 40 mg or none
Study: NCT00962936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-011
Description: CT-011
Study: NCT00332488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin & Secretagogues
Description: Metformin tablets,Secretagogues supplied as any of the currently marketed brands and formulations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin & Metformin
Description: Technosphere Insulin Inhalation Powder 15U/30U, Metformin tablets
Study: NCT02955706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-L-Carnitine
Description: TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Acetyl-L-Carnitine
Description: TID
Study: NCT03158935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cohort 1: i.v., 60mg/kg per day for 2 days Cohort 2: i.v., 30mg/kg per day for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cohort 1: i.v., 60mg/kg per day for 2 days Cohort 2: i.v., 30mg/kg per day for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Cohort 1: i.v., 25mg/m2 per day for 5 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Cohort 1 and 2: i.v., 200mg every 3 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Cohort 1 and 2: i.v., 200mg every 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-Infiltrating Lymphocytes (TILs)
Description: Cohort 1 and 2: i.v., 1x10\^10 - 1.6x10\^11 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-Infiltrating Lymphocytes (TILs)
Description: Cohort 1 and 2: i.v., 1x10\^10 - 1.6x10\^11 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2)
Description: Cohort 1 and 2: i.v., 125,000 IU/kg subcutaneous per day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2)
Description: Cohort 1 and 2: i.v., 125,000 IU/kg subcutaneous per day
Study: NCT01004029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL
Description: 1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
Study: NCT03384147

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drinking
Description: Five different types of alcohol given to participants for 4-5 days in a random sequence for 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drinking
Description: Five different types of alcohol given to participants for 4-5 days in a random sequence for 3 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abstaining
Description: Participants are abstaining from all alcoholic beverages for three weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abstaining
Description: Participants are abstaining from all alcoholic beverages for three weeks
Study: NCT02236663

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Safety Planing App
Description: The control group App will provide women and friends with basic safety planning information and a brief resource list of IPV resources. The resources will be targeted to college students age 18-24 years. The control group App safety plan is not personalized to woman/friend's safety priorities and danger in the relationship.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized App-Based Safety Decision Aid
Description: Setting of priorities for safety: participants will establish priorities by making pairwise comparisons of importance between 5 factors.~Danger Assessment: asks participants to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger and safety planning information and resources based on their level of danger.~Personalized action plan: Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented tailored to their level of danger and priority settings. The participant is given the option to print results and the personalized plan.